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Abstract 
Objectives: To investigate beliefs about medicines and their association with medicine 
adherence in patients with chronic diseases in China. 
Design: A cross-sectional questionnaire-based study  
Setting: Two large urban hospitals in Hefei and Tianjin, China  
Participants: Hospital inpatients (313 stroke patients) and outpatients (315 diabetic patients 
and 339 rheumatoid arthritis (RA) patients) were recruited between January 2014 and 
September 2014. 
Outcome measures: The Beliefs about Medicines Questionnaire (BMQ), assessing patients’ 
beliefs about the specific medicine (Specific-Necessity and Specific-Concerns) prescribed for 
their conditions (stroke/diabetes/RA) and more general background beliefs about 
pharmaceuticals as a class of treatment (BMQ-General Benefit, Harm and Overuse); the 
Perceived Sensitivity to Medicines scale (PSM) assessed patients’ beliefs about how sensitive 
they were to the effects of medicines and the Medication Adherence Report Scale. The 
association between non-adherence and beliefs about medicines was assessed using a logistic 
regression model.  
Results: Patients with diabetes mellitus had a stronger perceived need for treatment [mean 
(SD) Specific-Necessity score, 3.75 (0.40)] than patients with stroke [3.69 (0.53)] and RA 
[3.66 (0.44)] (p=0.049). Moderate correlations were observed between Specific-Concerns and 
General-Overuse, General-Harm and PSM (Pearson correlation coefficients, 0.39, 0.49 and 
0.49, respectively, p<0.01). 311 patients were non-adherent to their medicine [159 (51.0%) in 
the stroke group, 60 (26.7%) in the diabetes mellitus group and 62 (19.8%) in the RA group, 
p<0.01]. Across the whole sample, after adjusting for demographic characteristics non-
adherence was associated with patients who had higher concerns about their medicines (OR, 
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1.35, 95% CI 1.07-1.71) and patients who believed that they were personally sensitive to the 
effects of medications  (OR 1.44, 95% CI 1.16-1.85). 
Conclusion: The BMQ is a useful tool to identify patients at risk of non-adherence. In future, 
adherence intervention studies may use the BMQ to screen for patients who are at risk of 
non-adherence and to map interventional support.  
Funding: Research Innovation Fund, UCL School of Pharmacy. 
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Strengths and limitations of this study  
• First large study of beliefs about medicines in China 
• High response rate, reflecting generalisability of the study finding 
• A cross-sectional design implicating that the association between non-adherence and 
beliefs about medicines did not necessarily lead a causal relationship. 
• Self-reported adherence may not be the best measurement for medicine adherence. 
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Introduction  
Medicine plays an essential role in chronic disease management. However, it is recognised 
that only half of patients with chronic diseases take their medicines as prescribed.1 Stroke, 
diabetes mellitus and rheumatoid arthritis (RA) are three common chronic diseases which 
together affect over 10% of China’s population of 1.40 billion.2-5 Stroke is the leading cause 
of adult death and disability in China with an annual mortality rate of approximately 1.6 
million, or 157 per 100,000.6 Patients with chronic diseases often require multiple medicine 
treatments for their conditions and any associated symptoms and comorbidities. To obtain 
full benefit from treatment, patients need to adhere to these complex medicine regimens in 
order to control their disease and maintain health. However, in reality medicine management 
is sub-optimal and relates to physician inertia and patients’ poor adherence with therapy.7 The 
elderly, with high rates of co-morbidity and co-prescribing, tend to have poor adherence and 
are at particular risk of unwanted adverse effects from drugs.8,9 
 
Studies outside China have identified patients’ beliefs about medicines as an important 
determinant of non-adherence.10 A recent meta-analysis of 96 peer-reviewed studies 
involving over 24,000 patients across 24 long-term conditions and 18 countries showed that 
non-adherence was related to patients beliefs about medicines, measured by the Beliefs about 
Medicines Questionnaire (BMQ).10 These studies indicated that there was often a disconnect 
between the patients and prescribers view of the medicine. Many patients doubted their 
personal need for the treatment or harboured concerns and these beliefs are associated with 
non-adherence. Beliefs about medicines may also be relevant in China, particularly as there 
some evidence that trust between patients and health professionals may have diminished after 
China’s economic reform.11,12 Patients often do not trust their doctors and doubt the treatment 
including therapeutic treatment they received. It is possible that this may translate into 
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scepticism about prescribed medicines and non-adherence. The aim of this study was to 
understand beliefs about medicines in Chinese patients with stroke, diabetes mellitus and RA 
and to investigate whether these beliefs are associated with medicine non-adherence.  
 
Methods 
A cross-sectional study was conducted in two large teaching hospitals in China between 
January 2014 and November 2014. The study was approved by the local research ethics 
committees. 
 
Study populations and recruitment 
Patients with stroke were recruited from The Second Hospital, Tianjin Medical University, 
Tianjin, China and patients with diabetes mellitus and RA were recruited from Anhui 
Provincial Hospital, Anhui Medical University, Hefei, China. Both hospitals are large 
teaching hospitals and are level 3 general hospitals, the highest classification for quality care 
given by the China’s National Health and Family Planning Commission (NHFPC) for all 
public hospitals.13 Patients who had a clinical diagnosis of stroke, diabetes mellitus or RA 
who were judged by the healthcare professionals as able to answer questions were invited by 
the healthcare professionals to take part in the study when they were admitted to hospital 
(stroke patients) or came to hospital clinics (diabetic and RA patients) during the study 
period. Some patients may have co-morbidity. However, they were only included for the 
condition they were hospitalised or the condition from the specific outpatient clinics. They 
were asked to complete a questionnaire which took approximately 10-15 minutes. Study 
information was given to patients and verbal consent was obtained before they started to fill 
in the questionnaire. All invited patients returned their questionnaires. Since there is a lack of 
research on beliefs about medicines and medicine non-adherence in China, a target sample 
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size of 300 patients for each condition was chosen based on typical sample sizes used in 
similar surveys. A recent meta-analysis showed that small-moderate effect of psychological 
beliefs on medicine adherence was observed in 94 studies with an average sample size of 
266.10 Data collection started in January 2014 and lasted around 4 months for each condition 
and was stopped once the target numbers were reached (November 2014). 
 
Questionnaire measurement 
The questionnaire consisted of demographic information, the BMQ questionnaire,14 perceived 
sensitivity to medicines scale (PSM) and medicine adherence report scale (MARS).15 All 
scales were translated and back translated in accordance with the Originator’s conditions to 
create a Chinese version, (BMQ-Chinese © R Horne MARS-Chinese © R Horne, PSM-
Chinese © R Horne). The BMQ and MARS were translated into Chinese by Dr Li Wei, the 
principal investigator for this study. They were then sent to the co-authors, Profs Xiaomei Li 
and Xin Li for comments and further adaptation resulting in a final Chinese version of the 
BMQ.  
 
Demographic information included name, age, gender, education, occupation and duration of 
the condition. The BMQ questionnaire has two parts: the BMQ-Specific assessing beliefs 
about medicine used for a particular condition and the BMQ-General assessing beliefs about 
medicines in general. The details of the BMQ questionnaire can be found in a previous 
publication.8 In brief, BMQ-Specific comprised two scales: a 5-item treatment necessity scale 
Specific-Necessity and a 6-item treatment concern scale Specific-Concern. BMQ-General 
used three subscales: 1) General-Overuse (4 items), 2) General-Harm (4 items), and 3) 
General-Benefit (4 items). Perceived Sensitivity to Medicines (PSM) scale contained 5 items 
assessing perceptions of personal susceptibility to the effects of medicines. All BMQ items 
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and PSM were scored on a Likert type scale (where 1 = strongly disagree, 2 = disagree, 3 = 
uncertain, 4 = agree and 5 = strongly agree). A mean item score was then calculated as the 
sum of each item score divided by the number of items [for example, mean score of Specific-
Necessity= (N1+N2+N3+N4+N5)/5]. The Cronbach’s αs indicated that all scale measures 
were internally consistent in the study sample16 with high value of αpsm = 0.85, αconcern = 0.75 
and αnecessity = 0.64, and low values of αoveruse= 0.54, αharm = 0.55 and αbenefit = 0.58. For BMQ-
Specific, patients were only asked for the treatment prescribed for the diagnosed condition in 
the past 12 months. Medicine adherence was measured for the same period using the MARS 
scale consisting of 5 items with 25 score points in total. For example, one item is “I forget to 
take them”. 
 
Before the study commenced, 30 people including doctors, nurses, medical students and 
patients were asked to complete the questionnaire to assess whether the Chinese version of 
the BMQ, PSM and MARS would be easily understood by Chinese patients. Feedback was 
wholly positive; however we recognised that patients were likely to be elderly and may have 
poor literacy. Therefore, arrangements were made to provide help should patients have any 
difficulty completing the questionnaire. Patients in both centres completed the questionnaire 
either by themselves or with help from the healthcare professionals in the medical ward or 
clinic they attended. Healthcare professionals received a briefing from the local investigators 
on how to complete the questionnaire including instructions on how to explain the meaning 
of the questionnaire items without influencing patients’ responses. 
 
Definition of adherence and non-adherence 
It is commonly accepted that it is not necessary to take 100% of a prescribed treatment, and 
80% adherence is a commonly used cut-off to define adherence, especially in medicine 
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benefit/safety studies.17 While the MARS scale does not allow direct assessment of the 
percentage of prescribed treatment taken, we used a cut-off of 20 out of 25 on this scale to 
define adherence, indicating that patients are taking a large proportion of their prescribed 
doses. Adherence was calculated as sum of the scores from each item divided by the 
maximum points of 25 using the 5-item MARS scale. Non-adherent patients were defined as 
having a score <80% adherence to medicine.  
 
Attitudinal analysis 
Participants were categorized into attitudinal groups (i.e. Skeptical, Ambivalent, Indifferent 
and Accepting groups) based on whether they scored above or below the scale midpoint for 
BMQ necessity and concerns scales. Non-adherence was investigated between the groups.17 
 
Statistical analysis 
Data were presented as mean (SD) for continuous variables and as frequencies (%) for 
categorical variables. Chi-squared and analysis of variance (ANOVA) tests were performed 
to determine significant differences between the three diseases. Correlations were used to 
examine relationships between BMQ-General and BMQ-Specific subscales. Logistic 
regression analysis was employed to assess the association between non-adherence and 
medicine beliefs. Five percent of patients had at least one missing value in their BMQ 
answers and the total missing values were 0.3% for the whole BMQ items. A sensitivity 
analysis was done to include all patients with missing data replaced with imputed data in the 
multivariable analysis concluding all variables listed in Table 1. The multiple imputation 
analysis included all variables used in the final analysis with 10 imputations by using the 
Markov Chain Monte Carlo method to produce imputed data. All statistical analyses were 
carried out using SAS (version 9.4). 
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Results  
 
Patient characteristics  
There were 967 patients in the study (313 with stroke, 315 with diabetes mellitus and 339 
with RA). Table 1 shows the demographic and clinical information by disease groups. 
Patients with RA were significantly younger than patients with stroke and diabetes mellitus 
(mean age 49.7 vs 65.8 and 62.5, respectively). The RA group was 85% female while only 
44% of stroke patients and 45% of diabetes mellitus patients were female. Patients with RA 
were 5 times more likely to report having received no formal education than patients with 
stroke and diabetes mellitus (23.3% vs 4.8% and 4.1%, respectively). Over half of patients in 
the stroke group had less than 1 year disease duration while more than half of the patients in 
the RA and diabetes mellitus groups had more than 5 years disease duration.  
 
BMQ results 
The results of BMQ subscales are shown in Table 2. There were no significant differences in 
the mean scores of Specific-Concerns and General-Harm between the three groups. However, 
differences were observed for Specific-Necessity, General-Overuse, General-Benefit and 
PSM among the three groups. Patients with RA had the highest score of 3.75 (SD 0.40) for 
Specific-Necessity and lowest scores of 2.95 (SD 0.51) for General-Overuse and 3.55 (SD 
0.45) for General-Benefit. The mean scores of PSM were 2.89 (SD 0.65), 2.35 (SD 0.64) and 
2.70 (SD 0.68). The attitudinal analysis categorised patients into four groups (high/low 
necessity and high/low concerns) according to the midpoint of the Specific-Necessity 
Specific-Concerns scales shows that 45% of patients were classified as ‘Ambivalent’, 45%  
as ‘Accepting’,  4% as ‘Skeptical’ and 6% as ‘Indifferent’ (Figure 1). 
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Patients’ general beliefs about medicines were associated with their evaluations of the 
specific treatments they were taking. Table 3 shows the correlation between BMQ-General 
and BMQ-Specific. Specific-Necessity was positively associated with General-Benefit 
(Pearson correlation coefficients = 0.31, p<0.01). Moderate correlations were observed 
between Specific-Concerns and General-Overuse, General-Harm and PSM (Pearson 
correlation coefficients, 0.39, 0.49 and 0.49, respectively, p<0.01). General-Overuse was also 
correlated with General-Harm and PSM (Pearson correlation coefficients, 0.45 and 0.39, 
respectively, p<0.01). The Pearson correlation coefficient was 0.39 (p<0.01) for General-
Harm and PSM.  
 
Association between beliefs about medicines and non-adherence 
Three hundred and eleven patients were non-adherent to their medicine [159 (51.0%) in the 
stroke group, 60 (26.7%) in the diabetes mellitus group and 62 (19.8%) in the RA group, 
p<0.01]. After adjusting for demographic characteristics, Specific-Concerns and PSM were 
significantly associated with non-adherence (adjusted ORs, 1.35, 95% CI 1.07-1.71 and 1.44, 
95% CI 1.16-1.80). Negative associations between non-adherence and Specific-Necessity and 
General-Benefit were not statistically significant (Table 4). The subgroup analyses showed 
that the point estimates of Specific-Concerns were positively associated with non-adherence 
across the three conditions i.e. the more concerns about the medicines, the more non-adherent 
to medicines, with adjusted ORs ranging from 1.15 (95% CI 0.67-1.98) for diabetes mellitus 
to 1.43 (95% CI 1.02-2.00) for stroke (Table 5). The unadjusted results showed similar results 
across the three disease conditions. The sensitivity analysis showed that Specific-Concerns 
and PSM were positively associated with non-adherence (adjusted ORs, 1.15 95% CI 1.04-
1.26 and 1.40, 95% CI 1.04-1.26, respectively) and General-Benefit was negatively 
associated with non-adherence (adjusted OR 0.79, 95% CI 0.71-0.87). Compared with 
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patients in the Accepting group, patients in the other attitudinal groups were more likely to be 
the non-adherent (adjusted ORs, 1.50 95% CI 1.10-2.05 for the Ambivalent group, 1.27 95% 
CI 0.60-2.68 for the Skeptical group and 1.27 95% CI 0.69-2.34 for the Indifferent group. 
Only patients in the Ambivalent group showed a statistical significance.  
 
Discussion 
This is the first large study of this kind that investigates beliefs about medicines and medicine 
non-adherence in China in three common chronic diseases. Both unadjusted and adjusted 
results revealed that Specific-Concerns and PSM were significantly associated with non-
adherence i.e. the higher the concern about the medicine or the higher perceived sensitivity to 
medicines. Using the continuous MARS-5 scores showed similar relationships to those 
reported in logistic regression (r=-0.09, p<0.01 for Specific-Concerns and r=-0.09, p<0.01 for 
PSM). We noted differences between groups that might indicate different attitudes towards 
the diseases and their treatments or be attributable to other factors. The hospital out-patients 
(diabetes mellitus and RA) included some patients who had previous hospitalisations and 
come back to hospital for regular monitoring. 
Our findings were consistent with the evidence from a recent meta-analysis which showed 
that higher adherence was associated with fewer concerns about treatment10 but not consistent 
with previous findings that higher belief in personal need for treatment was associated with 
higher adherence; Specific-Necessity was not associated with non-adherence in our overall 
analysis. Subgroup analyses showed that patients with stroke and diabetes mellitus showed 
the same direction association as previous studies i.e, patients with higher necessity were less 
likely to be non-adherent. However, an opposite non-statistically significant result of 
Specific-Necessity and adherence for patients with RA (Our result of 1.34 (95% CI 0.73-
2.46) for non-adherence equals 0.75, 95% CI 0.41-1.38 for adherence) was observed in the 
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study in comparison with the meta-analysis result which had a pooled OR of 3.28, 95%CI 
1.11-9.71 for adherence.10 The point estimate could be due to chance and further studies need 
to confirm the finding. A recent study found that General-Benefit may be negatively 
associated with non-adherence among 398 patients with epilepsy from the UK primary care 
population (adjusted OR, 0.92, 95%CI 0.63-1.34)18 and this association was confirmed by our 
study with a borderline significant OR of 0.75 (95%CI 0.56-1.02). There was no correlation 
between Necessity and Concern (Table 2) in our study population and this was supported by 
a recent Swedish study conducted in 578 stroke patients.19 They reported a Spearman’s 
correlation coefficient of 0.075 (p=0.08). Compared to patients with high necessity and low 
concerns, patients with high necessity and high concerns, low necessity and high concerns, 
and low necessity and low concerns were all associated with non-adherence and this was 
supported by  studies conducted in patients with inflammatory bowel disease and renal 
dysfunction.20 21 High perceived sensitivity to medicines was reported to be associated with 
non-adherence and higher medical care utilisation, increased symptom reporting and greater 
information-seeking about medication.18, 22  Our study also showed PSM was associated with 
non-adherence. 
Our study has some strengths. Firstly, this was the first large BMQ study conducted in China. 
Secondly, we choose two large teaching hospitals for this study and collected data continually 
until the target numbers were reached for each condition. Therefore, our study population 
was more likely to represent the disease population from each region as large teaching 
hospitals provide health care service to majority of Chinese patients. However, we 
acknowledge that some patients with Transient Ischemic Attacks (TIAs), a subtype of stroke 
may not be admitted to hospital. Therefore our stroke in-patients may under represent the 
TIA patients. Thirdly, China has higher prevalence rates of stoke and diabetes mellitus than 
Western Europe and stroke is also the leading cause of death in China. In light of the current 
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deteriorated relationship between health professional and patients (i.e. patients do not trust 
their doctors and other health professionals, doctors, nurses are often abused verbally and 
physically by patients,11, 23, 24 more studies are needed from the patients’ perspective. More 
consideration from the patient perspective should be taken into account in term of chronic 
disease management and the relationship between patients and health professionals. 
However, our study was an observational study. Therefore the results may be confounded by 
unmeasured factors such as comorbidity. Self-reported adherence may not be the best 
measurement for medicine adherence as patients may, for example, underestimate how often 
they forget their treatment. However, a strong correlation was found for medicine adherence 
measured by self-reported questionnaire, electronic prescriptions and serum biomarkers in a 
recent intervention study suggesting that self-report is a reliable measure.25 Also our study 
found relatively low reliability of the BMQ general scales and further investigation and 
refinement might be needed of these Chinese translations. The difference in non-adherence 
between stroke and other conditions needs to be explored in future studies as disease itself 
may play an important role in medicine adherence.  
In conclusion, we found that the BMQ is a useful tool to identify psychological factors that 
are linked to non-adherence in patients with stroke, diabetes and RA. Future studies should 
use the BMQ to screen patients to identify those who are at high risk of non-adherence and 
map their treatment plan accordingly.  
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Table 1. Patient characteristics by conditions  
 Stroke 
n=313 (100%) 
Diabetes 
n=315 (100%) 
RA 
n=339 (100%) 
Age, mean (SD) * 65.8 (13.7) 62.5 (13.9) 49.7 (12.8) 
Gender†*     
   Women  136 (43.5%) 141 (44.8%) 287 (85.2%) 
   Men 177 (56.5%) 174 (55.2%) 50 (14.8%) 
Education*    
   Illiteracy (no formal 
education) 
15 (4.8%) 13 (4.1%) 79 (23.3%) 
   Primary school 66 (21.1%) 62 (19.7%) 93 (27.4%) 
   Junior high school  60 (19.2%) 91 (28.9%) 91 (26.8%) 
   High school/college 116 (37.1%) 77 (24.4%) 48 (14.2%) 
   University or above 54 (17.2%) 70 (22.2%) 25 (7.4%) 
   Unknown  2 (0.6%) 2 (0.6%) 3 (0.9%) 
Occupation*     
   Farmer  5 (1.6%) 22 (7.0%) 110 (32.5%) 
   Worker/clerk 83 (26.5%) 117 (37.1%) 38 (11.2%) 
   Housewife/unemployment  45 (14.4%) 12 (3.8%) 113 (33.3%) 
   Retirement   129 (41.2%) 54 (17.1%) 40 (11.8%) 
   Health professional  19 (6.1%) 29 (9.2%) 15 (4.4%) 
   Civil service  29 (9.3%) 72 (22.9%) 11 (3.2%) 
   Unknown  3 (1.0%) 9 (2.9%) 12 (3.5%) 
Duration of the disease*    
<= 1 year 178 (56.9%) 20 (6.4%) 55 (16.2%) 
   1-5 years 91 (29.1%) 74 (23.5%) 104 (30.7%) 
> 5 year 44 (14.1%) 220 (69.8%) 177 (52.2%) 
   unknown 0 (0.0%) 1 (0.3%) 3 (0.9%) 
†Excluding missing data; *<0.05 
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Table 2. Results of BMQ and PSM by disease conditions  
 Stroke 
n=313  
Diabetes 
n=315  
RA 
n=339  
Specific-Necessity (mean, SD) †* 3.69 (0.53) 3.75 (0.40) 3.66 (0.44) 
Specific-Concerns (mean, SD) † 3.03 (0.71) 3.15 (0.58) 3.07 (0.58) 
General-Overuse (mean, SD) †* 3.22 (0.62) 3.12 (0.50) 2.95 (0.51) 
General-Harm (mean, SD) † 2.94 (0.78) 2.95 (0.50) 2.99 (0.43) 
General-Benefit (mean, SD) †* 3.70 (0.53) 3.69 (0.42) 3.55 (0.45) 
PSM (mean, SD) †* 2.89 (0.65) 2.35 (0.64) 2.70 (0.68) 
MARS score (mean, SD*)  18.81 (4.16) 21.51 (3.07) 21.47 (3.86) 
†Excluding missing data; PSM=Perceived Sensitivity to Medicines; *<0.05 
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Table 3. Correlation matrix between BMQ-Specific, BMQ-General and PSM 
 Necessity Concerns Overuse Harm Benefit PSM 
 
Overall 
Necessity 1.00      
Concern 0.02(0.45) 1.00     
Overuse -0.01 (0.87) 0.39 (<0.01) 1.00    
Harm -0.05 (0.16) 0.49 (<0.01) 0.45 (<0.01) 1.00   
Benefit 0.31(<0.01) -0.09 (0.01) 0.11 (<0.01) 0.04 (0.21) 1.00  
PSM 0.04 (0.22) 0.45 (<0.01) 0.39 (<0.01) 0.38<0.01) 0.05 (0.14) 1.00 
 
Stroke 
Necessity 1.00      
Concern 0.04 (0.43) 1.00     
Overuse 0.06 (0.31) 0.50 (<0.01) 1.00    
Harm -0.06 (0.27) 0.66 (<0.01) 0.57 (<0.01) 1.00   
Benefit 0.36 (<0.01) 0.01 (0.88) 0.24 (<0.01) 0.13 (0.12) 1.00  
PSM 0.23 (<0.01) 0.52 (<0.01) 0.51 (<0.01) 0.50 (<0.01) 0.22 (<0.01) 1.00 
 
Diabetes mellitus 
Necessity 1.00      
Concern 0.02 (0.59) 1.00     
Overuse -0.05 (0.40) 0.26 (<0.01) 1.00    
Harm -0.08 (0.20) 0.21 (<0.01) 0.44 (<0.01) 1.00   
Benefit 0.19 (<0.01) -0.07 (0.26) 0.18 (<0.01) 0.08 (0.19) 1.00  
PSM -0.08 (0.20) 0.36 (<0.01) 0.38 (<0.01) 0.44 (<0.01) 0.07 (0.23) 1.00 
 
RA 
Necessity 1.00      
Concerns 0.01 (0.91) 1.00     
Overuse -0.08 (0.13) 0.41 (<0.01) 1.00    
Harm 0.02 (0.72) 0.42 (<0.01) 0.30 (<0.01) 1.00   
Benefit 0.30 (<0.01) -0.21 (<0.01) -0.20 (<0.01) -0.15 (0.21) 1.00  
PSM -0.04 (0.52) 0.54 (<0.01) 0.29 (<0.01) 0.27 (<0.01) -0.13 (0.02) 1.00 
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Table 4. Odd ratios of medicine non-adherence  
 Unadjusted   
OR, 95% CI 
Adjusted* 
OR, 95% CI 
Specific-Necessity 0.90, 0.67-1.21 0.93, 0.68-1.27 
Specific-Concerns  1.27, 1.02-1.58 1.35, 1.07-1.71 
General-Overuse 1.32, 1.04-1.69 1.15, 0.88-1.50 
General-Harm 1.09, 0.87-1.38 1.12, 0.89-1.43 
General-Benefit 0.84, 0.63-1.12 0.75, 0.56-1.02 
PSM 1.72, 1.41-2.09 1.44, 1.16-1.85 
*Adjusted for age, gender, education, occupation, duration of the disease and different 
diseases 
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Table 5. Odd ratios of medication non-adherence by disease groups 
 Stroke  Diabetes  RA 
 Unadjusted   
OR, 95% CI 
Adjusted* 
OR, 95% CI 
 Unadjusted   
OR, 95% CI 
Adjusted* 
OR, 95% CI 
 Unadjusted   
OR, 95% CI 
Adjusted* 
OR, 95% CI 
Specific-
Necessity 
0.83, 0.54-1.26 0.92, 0.59-1.43  0.71, 0.35-1.40 0.92, 0.43-1.97  1.31, 0.75-2.27 1.34, 0.73-2.46 
Specific-
Concerns  
1.43, 1.04-1.96 1.43, 1.02-2.00  1.16, 0.71-1.88 1.15, 0.67-1.98  1.38, 0.91-2.12 1.32, 0.84-2.10 
General-
Overuse 
1.26, 0.88-1.81 1.24, 0.85-1.82  1.12, 0.64-1.96 1.10, 0.61-2.00  1.06, 0.66-1.71 0.98, 0.60-1.60 
General-
Harm 
1.26, 0.95-1.68 1.30, 0.96-1.77  0.58, 0.32-1.05 0.59, 0.32-1.11  1.27, 0.72-2.24 1.27, 0.70-2.30 
General-
Benefit 
0.87, 0.57-1.32 0.83, 0.53-1.29  0.78, 0.41-1.50 0.83, 0.41-1.69  0.64, 0.37-1.09 0.65, 0.37-1.13 
PSM 1.76, 1.22-2.53 1.79, 1.23-2.60  1.60, 1.05-2.44 1.73, 1.10-2.70  1.06, 0.74-1.51 1.01, 0.70-1.48 
*Adjusted for age, gender, education, occupation, duration of the disease 
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Figure legend  
Figure 1. Attitudinal analysis of BMQ-Specific. 
